Patents by Inventor Tom HODGE

Tom HODGE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210292406
    Abstract: An injectable formulation, comprising: poly(lactic-co-glycolic (PLGA) microsphere encapsulating siltuximab, wherein microspheres are sized to release siltuximab over a period of hours, days and weeks, where the biocompatible polymer releases antibody at an absorption rate which is characterized by an absorption rate constant (Ka (h?1) in the range of (0.001 to 2.048)+/?20%, or +/?10%, or +/?5%. for use and treating human patients with infections. The invention includes treating patients with viral infections of SARS-Cov-2 using siltuximab.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 23, 2021
    Applicant: Flow Pharma, Inc.
    Inventors: Reid M. Rubsamen, Scott Burkholtz, Charles V. Herst, Tom Hodge, Lu Wang
  • Publication number: 20210145960
    Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.
    Type: Application
    Filed: October 6, 2020
    Publication date: May 20, 2021
    Applicant: ORGENESIS INC.
    Inventors: Jamie SULLEY, Luis SQUlQUERA, David SIDRANSKY, Tom HODGE
  • Patent number: 10835598
    Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 17, 2020
    Assignee: ORGENESIS INC.
    Inventors: Jamie Sulley, Luis Squiquera, David Sidransky, Tom Hodge
  • Publication number: 20170296647
    Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 19, 2017
    Inventors: Jamie SULLEY, Luis SQUIQUERA, David SIDRANSKY, Tom HODGE